Scholarlink

<p>The single-nucleotide polymorphism (SNP) rs1800693 in the tumor necrosis factor receptor 1 (TNFR1) gene leads to the formation of a protein-mimicking effect of TNF-α inhibitors, which are agents used to treat sarcoidosis. We investigated the association between rs1800693 and disease progression in two populations with non-Lofgren sarcoidosis (nLS). We genotyped two nLS cohorts (Ruhrlandklinik, Germany, <i>n</i> = 108, and the HUNT study, Norway, <i>n</i> = 393), and two control groups with (<i>n</i> = 313) and without (<i>n</i> = 2414) COPD for rs1800693 (A/G polymorphism). Pulmonary function tests at inclusion and at the end of follow-up were compared according to genotype. The mean follow-up times were 6.5 (German) and 7.9 (Norwegian) years. German AA patients had an absolute decline in %pred FVC (-8.5, 95% CI -3.4, -13.6) and DLco (-4.9, 95% CI -0.1, -9.7). In AG/GG (G+), the absolute decline in FVC was less pronounced (-3.9, 95% CI -1.1, -6.8), and DLco was stable. In the Norwegian patients, the decrease in lung function was similar between the AA and G+ groups. Compared with homozygous GG, homozygous AA was associated with a lower FVC %pred at baseline (-5.7, 95% CI -0.2, -11.6) and at the end of follow-up (-7.0, 95% CI -0.1, -14.0). Genotype was not associated with lung function in either control group. TNFR1 rs1800693 might be associated with lung function impairment and decline in non-Lofgren sarcoidosis patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of the TNFRSF1A genotype with lung function impairment in patients with sarcoidosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • A. G. Lunde,
  • S. Romundstad,
  • A. H. Henriksen,
  • H. Sorger,
  • E. Boerner,
  • N. Schröder,
  • F. Bonella

摘要

The single-nucleotide polymorphism (SNP) rs1800693 in the tumor necrosis factor receptor 1 (TNFR1) gene leads to the formation of a protein-mimicking effect of TNF-α inhibitors, which are agents used to treat sarcoidosis. We investigated the association between rs1800693 and disease progression in two populations with non-Lofgren sarcoidosis (nLS). We genotyped two nLS cohorts (Ruhrlandklinik, Germany, n = 108, and the HUNT study, Norway, n = 393), and two control groups with (n = 313) and without (n = 2414) COPD for rs1800693 (A/G polymorphism). Pulmonary function tests at inclusion and at the end of follow-up were compared according to genotype. The mean follow-up times were 6.5 (German) and 7.9 (Norwegian) years. German AA patients had an absolute decline in %pred FVC (-8.5, 95% CI -3.4, -13.6) and DLco (-4.9, 95% CI -0.1, -9.7). In AG/GG (G+), the absolute decline in FVC was less pronounced (-3.9, 95% CI -1.1, -6.8), and DLco was stable. In the Norwegian patients, the decrease in lung function was similar between the AA and G+ groups. Compared with homozygous GG, homozygous AA was associated with a lower FVC %pred at baseline (-5.7, 95% CI -0.2, -11.6) and at the end of follow-up (-7.0, 95% CI -0.1, -14.0). Genotype was not associated with lung function in either control group. TNFR1 rs1800693 might be associated with lung function impairment and decline in non-Lofgren sarcoidosis patients.